Document:

EXHIBIT 10.6

 

EXHIBIT
10.6

 

PRODUCT
DISTRIBUTION OPTION AGREEMENT

 

(the
“Agreement”)

 

ENTERED
INTO this 22st day of January, 2015 (the “Effective Date”)

 

	BETWEEN:	KNIGHT
    THERAPEUTICS (BARBADOS) INC., a corporation formed
	 	under the laws
    of Barbados;
	 	(hereinafter referred
    to as “Optionee”);

 

	AND:	SYNERGY
    STRIPS CORP., a corporation formed under the laws of
	 	the State of Nevada;
	 	(hereinafter referred
    to as “Optioner”).

 

PREAMBLE

 

WHEREAS
Optionee has agreed to grant a loan (the “Loan”) to Optioner pursuant to the terms and conditions of that certain
credit agreement between the Optionee and the Optioner dated as of the date hereof (the “Credit Agreement”);

 

WHEREAS
the Loan is granted in consideration for, among other things, an option on the exclusive distribution right on Products (as this
term is defined in Schedule A hereto) in Canada;

 

WHEREAS
the option on the right to distribute Products in Canada will be governed by the terms and conditions set forth in this Agreement;

 

NOW,
THEREFORE, in consideration of the covenants contained herein and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree as follows:

 

	1.	GENERAL
	 	 
	1.1	Preamble and Schedules. The preamble
    herein and schedule which is attached to this Agreement are incorporated into this Agreement by reference and are deemed to
    be part hereof.
	 	 
	1.2	Choice of Law and Attornment. This
    Agreement and all rights and obligations hereunder, including matters of construction, validity and performance, shall be
    governed by and construed in accordance with the laws applicable in the Province of Quebec, Canada. Any dispute arising in
    connection with this Agreement shall be resolved exclusively in the district of Montreal through the courts of Quebec, Canada.
	 	 
	2.	OPTION
	 	 
	2.1	Optioner hereby grants to Optionee
    an exclusive right to negotiate the exclusive distribution right for any one or more Products for the territories of Canada,
    Russia, Sub-Sahara Africa and Israel (each a “Territory” and collectively, the “Territories”) pursuant
    to the parameters detailed in Schedule A attached hereto (the “Option”).
	 	 
	2.2	The Option shall commence on the Effective
    Date of this Agreement and, unless extended by mutual written agreement between the parties, shall subsist until January 31,2045
    (the “Option Period”) and will be automatically renewed for successive additional five (5) year periods, unless
    either party provides a notice of termination prior to the then applicable Option Period expiry date.
	 	 
	2.3	Subject to the Loan being granted by
    Optionee to Optioner, the Option may be exercised by Optionee at any time or from time to time during the Option Period by
    serving a written notice to Optioner indicating its will to exercise the Option (the “Exercised
    Option”). The notice shall specify which one
    or more Products the Optionee wishes to distribute and which one or more of the Territories it wishes to distribute the Produces)
    in.

 

    	 

    	 

    

 

	2.4	Upon
    Optioner’s receipt of a written notice indicating the Optionee’s intent to exercise the Option, the Parties shall
    have a maximum delay of ninety (90) days to negotiate in good faith, conclude and execute the final terms and conditions of
    a distribution agreement based on the terms detailed in the Schedule A of the Agreement (the “Exercised
    Option Period”).
	 	 
	2.5	During
    the Exercised Option Period, Optioner will continue to be responsible for the preparation, filing, prosecution, maintenance
    and defence of the patents and regulatory approvals for the Products in the applicable Territory and costs related thereto.
	 	 
	2.6	Should
    Optionee not exercise the Option within the Option Period, Optioner shall thereafter be free to enter into agreements or distribution
    arrangements regarding the distribution rights for Products in the Territories on terms and conditions that are not more favourable
    to the third party than those offered by Optionee. Should the Parties not execute a distribution agreement within the Exercised
    Option Period provided for in Section 2.4 in respect of Produces) or Territories that were the subject of an Exercised Option,
    Optioner shall thereafter be free to enter into any agreements or arrangements regarding the distribution rights for such
    Produces) and such Territories.
	 	 
	2.7	All
    intellectual property disclosed and materials transferred by the Optioner to the Optionee pursuant to this Agreement do not
    in any way imply a transfer of any of Optioner’s ownership rights in said intellectual property disclosed and shall
    remain the exclusive property of the Optioner.
	 	 
	2.8	In
    the event that Optioner acquires a Product for which a third party has a pre-existing exclusive Territory license prior to
    (i) Optioner signing a letter of intent relating to the Product, or (ii) 60 days prior to Optioner reaching definitive agreements
    relating to the Product, the licensor will be entitled to maintain the license until the expiry date of such pre-existing
    license at which time the license will, at Optionee’s option, be transferred to Optionee on the terms set forth in Schedule
    A.
	 	 
	3.	NOTICE

 

Any
notices served under this Agreement shall be made in writing and sent by registered or recorded delivery post address to:

 

	 	If
    to the Optioner:	Synergy
    Strips Corp.
	 	 	Attn: Jack Ross
    865 
	 	 	Spring Street
	 	 	Westbrook ME
	 	 	04092
	 	 	 
	 	with
    a copy to:	Wyrick
    Robbins Yates & Ponton LLP
	 	 	Attn: W. David
    Mannheim 4101
	 	 	Lake Boone Trail,
    Suite 300
	 	 	Raleigh, NC 27607
	 	 	 
	 	If
    to the Optionee:	Chancery
    House
	 	 	High Street
	 	 	Bridgetown, St.
    Michael
	 	 	BB11128 Barbados,
    Wl
	 	 	 
	 	To the
    attention of:	Andrew
    C. Ferreira +1-246-431-0076
	 	Fax No.:	 
	 		

                                                         DAVIES
                                         WARD PHILLIPS & VINEBERG S.E.N.C.R.L., s.r.I./LLP Attn: Hillel W. Rosen 900
                                         Third Avenue 24th Floor

        New
        York, NY 10022 U.S.A.

 

With
a copy to: 4

 

 

 

Neither
party shall be entitled to assign, transfer or sub-contract nor give as a security interest, the Option right under this Agreement
without the prior written consent of the other party, such consent not to be unreasonably withheld or delayed.

 

[Signature
Page Follows]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF the parties have executed this Agreement, as follows:

 

	 	

    SYNERGY STRIPS CORP.
	 	 	 
	 	Per:	/s/
    Jack Ross
	 	Name:	Jack Ross
	 	Title:	CFO and Corporate
    Secretary
	 	 	 
	 	KNIGHT
    THERAPEUTICS 
	 	(BARBADOS) INC.
	 	 
	 	Per:	/s/[Unintelligible]
	 	Name:	Chancery Corporate
    Services Limited
	 	Title:	Secretary

 

Signature
Page to Product Distribution Option Agreement

 

    	 

    	 

    

 

SCHEDULE
A

 

TERM
SHEET

 

The
following sets out the terms for a distribution agreement contemplated between the Optioner and the Optionee (also referred to
as “Synergy” and “Knight” respectively in this Schedule A), in relation to the Products. The terms set
out below are intended to set out the material commercial terms to be included in the final distribution agreement to be entered
into between the parties. The Optioner and the Optionee acknowledge that they shall not renegotiate said material commercial terms
unless both parties agree to do so based on good faith negotiations. The parties acknowledge that entering into the arrangement
contemplated by these terms is subject to good faith negotiation of the terms of a legally binding distribution agreement. The
terms defined in the body of the Agreement shall continue to apply for this Schedule A.

 

	1.
    Rights granted	Exclusive
    distribution right for Products in Canada, Russia, Sub-Sahara Africa and/or Israel (each a “Territory”) for no
    less than 15 years.
	 	 
	2.
    Products	“Products”
    means all of Synergy’s and its Affiliate’s current and future products, including the FOCUSFactor product.
	 	 
	3.
    Supply Cost	Knight
                                         would pay to Synergy the Cost of Goods plus 10% of the Cost of Goods resulting from the
                                         sales of the Products in the applicable Territory.

        “Cost
        of Goods” means, with respect to the Products, the production cost of such Products (for the avoidance of doubt,
        including manufacturing oversight and quality assurance) calculated in accordance with internal cost accounting methods
        consistently applied by Synergy for its other similar pharmaceutical products; provided, that such methods comply with
        IFRS. Cost of Goods shall include direct labor, direct materials (including taxes and duties), but exclude corporate administrative
        overhead, any costs associated with excess capacity, any royalties or license fees payable to third parties and any other
        indirect costs. Notwithstanding the foregoing, in the event the Product is manufactured by a third party supplier and
        procured by Synergy, the “Cost of Goods” shall include the costs charged for such Product by such third party
        supplier to Synergy.

	 	 
	4.
    Term	15
    years from date of commercial launch in the applicable Territory of the applicable Product with successive automatic renewals
    of 15 years each, unless Synergy pays the Repurchase Amount.
	 	 
	5.
    Synergy’s repurchase of distribution rights	Should
                                         Synergy wish to repurchase the distribution right on a Product for Territories from Knight
                                         in lieu of the automatic renewal referred to above, it may do so by paying to Knight
                                         the Repurchase Amount, being an amount equal to the Net Sales for the Product in the
                                         Territories over the previous 24 months prior to the end of the applicable Term.

                                                                               

        “Net
        Sales” means the gross amounts invoiced by or on behalf of Knight and its Affiliates (defined below) for sales of
        Products to third parties that are not Affiliates of Knight in bona fide, arms-length transactions, less the following
        deductions if and to the extent they are (i) determined in accordance with Knight’s accounting standards which are
        in accordance with IFRS, (ii) actually taken by Knight or its Affiliates and (iii) included in the gross invoiced sales
        price of any Products or otherwise directly paid or incurred by Knight or its Affiliates with respect to the sale of Products:

	 	 

    	 

    	 

    

 

	 	(a)
                                         cash discounts;

                                                                               

        (b)
        rebates;

         

        (c)
        direct to customer discounts;

         

        (d)
        charge-backs;

         

        (e)
        bad debt;

         

        (f)
        amounts repaid or credited by reasons of defects, rejections, recalls, returns; and

         

        (g)
        tariffs, duties, excise, sales, value-added and other similar taxes (other than taxes
        based on income).

         

        “Affiliate”
        means any entity that directly or indirectly controls, is controlled by, or is under
        common control with the subject entity.

         

        “Control”,
        for purposes of this definition, means direct or indirect ownership or control of more than 50% of the voting interests
        of the subject entity.

	 	 
	6.
    Covenants of Knight	Knight
                                         would agree to perform, among other things, each of the following covenants:

                                                                               

        (a)
        Preparing and filing all applications and seeking regulatory approvals in the applicable
        Territory for the Products, including the payment of fees in connection therewith;

         

        (b)
        Assuming the reasonable costs of intellectual property filings (including trademark
        filings), procurement and maintenance for all intellectual property applications and registrations associated with the
        Products in the applicable Territory, provided that, notwithstanding any limited licence thereof, ownership of all intellectual
        property rights relating to the Products shall remain the exclusive property of Synergy;

         

        (c)
        Assuming all marketing, sales and distribution expenses related to the promotion of
        the Products in the applicable Territory; and

         

        (d)
        Preparing an annual marketing and sales plan relating to the Products in the applicable
        Territory.

	 	 
	7.
    Covenants of Synergy	Synergy
                                         would agree to perform, among other things, each of the following covenants:

                                                          

        (a)
        Providing Knight with all documentation relating to the submissions for regulatory approval
        to the U.S. Food and Drug Administration or the European Medicines Agency for the Products within one month from submission;

         

        (b)
        Where applicable, providing reasonable assistance to Knight with the regulatory submission
        of the Products in the applicable Territory;

         

        (c)
        Providing full assistance and cooperation with respect to securing intellectual property
        protection in the applicable Territory for the Products (including reasonable trademark protection), provided that, notwithstanding
        any limited licence thereof, ownership of all intellectual property rights relating to the Products shall remain the exclusive
        property of Synergy;

         

        (d)
        Not to assign the intellectual property associated with the Products to any third party,
        other than (i) to wholly owned affiliates of

	 

    	 

    	 

    

 

	 	Synergy,
                                         or (ii) in connection with a sale of all or substantially all of the assets of Synergy;

                                                                               

        (e)
        Selling the Products in finished packaged
        form to Knight;

         

        (f)
        Coordinating launch activities with Knight,
        including pharmacovigilence, pricing, reimbursement, positioning and health care conferences;

         

        (g)
        Providing international marketing and sales
        materials;

         

        (h)
        Providing trademarks for the applicable Territory.

	 	 
	8.
    Right to sublicense	Knight
    shall have the right to sublicense its distribution rights on Products or to use third party service providers for the distribution
    of the Products in the applicable Territory.
	 	 
	9.
    Others Provisions	If
    the Option is exercised by Knight, a complete distribution agreement including all the other terms and conditions usually
    used in such agreement will be prepared by Knight in the English language and presented to Synergy for negotiation in good
    faith. The parties agree to use the FOCUSFactor Distribution Agreement as their standard agreement, as applicable.EXHIBIT 10.7

 

EXHIBIT
10.7

 

DISTRIBUTION,
LICENSE AND SUPPLY AGREEMENT

 

THIS
AGREEMENT, effective January 22, 2015, by and between SYNERGY STRIPS
CORP., a corporation formed under the laws of the State of Nevada (“Synergy”)
and KNIGHT THERAPEUTICS (BARBADOS) INC., a
corporation incorporated under the laws of Barbados (“Knight
)

 

RECITALS

 

WHEREAS
Synergy owns or licenses all right, title and interest in and to certain patents, trademark(s) and Know-How relating to an ingestible
dietary supplement product known as FOCUSFactor and including FOCUSFactor Kids;

 

WHEREAS
Synergy owns or licenses all right, title and interest in and to certain patents, trademark(s) and Know-How relating to an ingestible
dietary supplement product known as Synergy Strips;

 

WHEREAS
Knight wishes to be appointed by Synergy as exclusive distributor, to offer to sell and sell the Licensed Products in the Territory
and Synergy is willing to grant such exclusive appointment;

 

WHEREAS
Knight wishes to procure the Licensed Products from Synergy and Synergy wishes to supply the Licensed Products to Knight;

 

NOW
THEREFORE in consideration of the mutual promises and covenants contained herein, the Parties, intending to be legally bound,
agree as follows:

 

	1	DEFINITIONS

 

	1.1	Definitions.
    The following terms as used hereinafter in this Agreement
    shall have the meaning set forth in this Section:

 

“Additional
Territory” has the meaning set forth in Section 11.

 

“Adverse
Drug Reaction” means a noxious and unintended response
to a drug, which occurs at doses normally used or tested for the diagnosis, treatment, or prevention of a disease or the modification
of an organic function.

 

“Adverse
Drug Event” means any untoward medical occurrence in a
patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a
causal relationship with this treatment.

 

“Affiliate”
means any corporation, firm, partnership or other entity that directly or indirectly controls, is controlled by or is under
common control with a Party, with “control” meaning ownership of greater than fifty percent (50%) of the voting stock
or other voting interests in the Party or the right to receive over fifty percent (50%) of the profits or earnings of the Party.
Such other relationship as in fact results in actual control over the management, business, and affairs of a Party shall also
be deemed to constitute control.

 

    	 

    	 

    

 

“Agreement”,
“hereto”, “hereunder”, “herein” and
similar expressions mean this License, Development and Supply Agreement.

 

“Applicable
Laws” means any law, regulation, rule, guidance, order,
judgment or decree having the force of law in the Territory.

 

“Business
Day” means any day other than (i) Saturday or Sunday or
(ii) a day that is a legal holiday in either of Barbados or New York, New York, or (iii) any other day on which banks in either
of Barbados or New York, New York are required to be closed.

 

“Calendar
Quarter” means the three (3) month periods ending on March
31, June 30, September 30 and December 31 in each Calendar Year.

 

“Calendar
Year” means, in respect of any particular year, the one
(1) year period beginning on January 1 and ending on
December 31.

 

“Commercial
Sale” means any shipment of the Licensed Products in the
Territory pursuant to an arm’s length sale by Knight or its Affiliates to a Third Party.

 

“Commercialize”
means marketing, using, distributing, promoting, offering for
sale, and selling the Licensed Products.

 

“Cost
of Goods” means, with respect to the Licensed Products,
the production cost of such Licensed Products (for the avoidance of doubt, including, without limitation, manufacturing oversight
and quality assurance) calculated in accordance with internal cost accounting methods consistently applied by Synergy for its
other similar pharmaceutical products; provided, that such methods comply with IFRS. Cost of Goods shall include direct labor,
direct materials (including taxes and duties), but exclude corporate administrative overhead, any costs associated with excess
capacity, any royalties or license fees payable to third parties and any other indirect costs. Notwithstanding the foregoing,
in the event a Licensed Product is manufactured by a Third Party supplier and procured by Synergy, the “Cost of Goods”
shall include the costs charged for such Licensed Product by such Third Party supplier to Synergy.

 

“Effective
Date” means the date specified in the initial paragraph
of this Agreement.

 

“Force
Majeure” has the meaning set forth in Section 12.6.

 

“GMP”
means good manufacturing practices as required under the rules
of the applicable Governmental Authority in the Territory.

 

“Governmental
Authority” means any federal, state, provincial, or municipal
government body, commission, agency, board, court or tribunal in the Territory and having jurisdiction in the particular circumstances.

 

    	 

    	 

    

  

“IFRS”
means, at any time, the International Financial Reporting Standards, promulgated by the International Accounting Standards
Board, as amended, supplemented or replaced from time to time.

 

“Improvements”
means any new indications, dosage strengths, reformulations,
line extensions or other advances in, modifications or improvements to the Licensed Products.

 

“Initial
Term” has the meaning set forth in Section 9.1.

 

“Know-How”
means all scientific, technical, manufacturing, marketing, production,
sales and other information relating to the Licensed Products that is known to or controlled by Synergy and which is reasonably
necessary for the Commercialization of the Licensed Products in accordance with the terms of this Agreement.

 

“Launch”
means the date of the first Commercial Sale in the Territory
of the applicable Licensed Product.

 

“Licensed
Products” means each of FOCUSFactor, FOCUSFactor Kids
and Synergy Strip and all Improvements thereto. “Licensed
Product” means either of them.

 

“Long
Term Inability to Supply” shall mean the inability to
supply at least seventy percent (70%) of the volumes of a Licensed Product indicated in the current forecast that exceeds one
hundred and twenty (120) days.

 

“Knight
Indemnified Party” has the meaning set forth in Section
8.5.

 

“Net
Sales” means the gross amounts invoiced by or on behalf
of Knight and its Affiliates for sales of Products to third parties that are not Affiliates of Knight in bona fide, arm’s-length
transactions, less the following deductions if and to the extent they are (i) determined in accordance with Knight’s accounting
standards which are in accordance with IFRS, (ii) actually taken by Knight or its Affiliates and (iii) included in the gross invoiced
sales price of any Licensed Products or otherwise directly paid or incurred by Knight or its Affiliates with respect to the sale
of Licensed Products:

 

	 	(a)	cash
    discounts;
	 	 	 
	 	(b)	rebates;
	 	 	 
	 	(c)	direct
    to customer di scounts;
	 	 	 
	 	(d)	charge-backs;
	 	 	 
	 	(e)	bad
    debt;
	 	 	 
	 	(f)	amounts
    repaid or credited by reasons of defects, rejections, recalls, returns; and
	 	 	 
	 	(g)	tariffs,
    duties, excise, sales, value-added and other similar taxes (other than taxes based on income).

 

“Non-Renewal
Fee” has the meaning set forth in Section 9.7.

 

“Non-Renewal
Notice” has the meaning set forth in Section 9.1.

 

    	 

    	 

    

 

 

“Party”
means either Synergy or Knight and “Parties”
means both Synergy and Knight.

 

“Regulatory
Approval” means any and all approvals, marketing authorizations,
registrations and licenses (including amendments and supplements thereto) necessary from a Governmental Authority for the Commercialization
or manufacture of the Licensed Products in or for the Territory.

 

“Regulatory
Submissions” means all applications, filings, dossiers
and the like submitted to a Governmental Authority for the purpose of obtaining Regulatory Approval.

 

“Renewable
Term” has the meaning set forth in Section 9.1.

 

“SDEA”
means the Safety Data Exchange Agreement to be entered into
by the Parties within ninety (90) days after the Effective Date.

 

“Short
Term Inability to Supply” shall mean the inability to
supply at least seventy percent (70%) of the volumes of a Licensed Product indicated in the current forecast that continues for
more than sixty (60) days but less than one hundred and twenty (120) days.

 

“Specifications”
means the finished product specifications for each Licensed
Product as required by the applicable Regulatory Approval and as may be modified from time to time in accordance with the provisions
of this Agreement.

 

“Supply
Price” has the meaning set forth in Section 6.2.

 

“Synergy
Indemnified Party” has the meaning set forth in Section
8.6.

 

“Synergy
Marks” means the trade-marks “FOCUSFactor”,
and any other marks Synergy may adopt for use for the Licensed Products.

 

“Synergy
Patents” means all patents in the Territory, including
patent applications, continuations, divisional patents, re-examined patents, reissued patents, and foreign equivalents thereof,
that are owned by or licensed to Synergy which claim inventions reasonably necessary for the Commercialization of the Licensed
Products in the Territory.

 

“Term”
means the Initial Term or a Renewal Term.

 

“Territory”
means Canada and, subject to Section 12, may also include one
or more of the Additional Territories.

 

“Third
Party” means any person other than the Parties and their
Affiliates.

 

	1.2	Other
    Definitional and Agreement References. References to any
    agreement, contract, statute, act, or regulation are to that agreement, contract, statute, act, or regulation as amended,
    modified or supplemented from time to time in accordance with the terms hereof and thereof

 

    	 

    	 

    

  

	1.3	Ambiguities.
    Ambiguities, if any, in this Agreement shall not be construed
    against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.
	 	 
	1.4	Sections
    and Headings. The term “Section” refers to the
    specified Section of this Agreement, unless otherwise specified. Headings and captions of the Sections hereof are for convenience
    only and are not to be used in the interpretation of this Agreement.
	 	 
	1.5	Canadian
    Dollars. References in this Agreement to “Dollars”
    or “$” shall mean the legal tender of the United States, unless otherwise noted.
	 	 
	1.6	Date
    References. References from or through any date mean, unless
    otherwise specified, from and including or through and including, respectively.
	 	 
	1.7	Gender.
    Words of one gender include the other gender.
	 	 
	1.8	Include,
    Includes, Including. Whenever the words “include”,
    “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words
    “without limitation”, whether or not they are in fact followed by those words or words of like import.
	 	 
	1.9	Solidary
    Obligations. Unless specified otherwise in this Agreement,
    the obligations of any Party consisting of more than one person are solidary (joint and several).
	 	 
	1.10	No
    Strict Construction. This Agreement has been prepared jointly
    and shall not be strictly construed against either Party.
	 	 
	1.11	Number
    of Days. Whenever this Agreement refers to a number of days,
    unless otherwise specified, such number shall refer to calendar days.
	 	 
	1.12	Party
    References. Reference to any Party includes the successors
    and permitted assigns of that Party.
	 	 
	1.13	Singular/Plural.
    Words using the singular or plural number also include the
    plural or singular number, respectively.

 

	2.	GRANT
                                         OF RIGHTS

 

	2.1	Appointment.
    Subject to the terms of this Agreement, Synergy, on behalf
    of itself and its Affiliates, hereby appoints Knight as its exclusive distributor of Licensed Products in the Territory for
    the Term and further grants to Knight and Knight hereby accepts, for the Term, and for the Territory only, an exclusive license
    under the Synergy Patents and Know-How to Commercialize the Licensed Products.
	 	 
	2.2	Sublicensing.
    Knight may sublicense its rights granted hereunder or use
    sub-distributors or third party service providers to exercise its right or fulfill its obligations hereunder. All sublicense
    agreements, distribution or other arrangements or agreements shall be consistent with the terms and conditions of this Agreement,
    and Knight assumes full responsibility for any actions taken by or omissions by any sublicensee, distributor or other party
    and any of the expenses, costs, or fees incurred by any sublicensee, distributor or other party.

 

    	 

    	 

    

  

	2.3	No
    Implied Licenses. Neither Party grants to the other Party
    any right or license to use any of its intellectual property, Know-How or other proprietary information, materials or technology,
    or to practice any of its patent, trademark, or trade dress rights, except as expressly set forth in this Agreement.
	 	 
	2.4	Restriction
    on Knight Sales. Knight shall not: (i) knowingly solicit
    or accept orders for distribution of Licensed Products to a Third Party outside the Territory; (ii) knowingly distribute any
    Licensed Products for sale or use outside the Territory; or (iii) supply any Third Party that has distributed or offered to
    distribute Licensed Products outside the Territory after Knight has actual knowledge that said Third Party has distributed
    or offered to distribute Licensed Products obtained from Knight outside of the Territory.
	 	 
	2.5	Restriction
    on Synergy Sales. Synergy shall not: (i) knowingly solicit
    or accept orders for distribution of Licensed Products to a Third Party for sale or distribution in the Territory; (ii) knowingly
    distribute any Licensed Products for sale or use in the Territory; or (iii) supply any Third Party that has distributed or
    offered to distribute Licensed Products in the Territory after Synergy has actual knowledge that said Third Party has distributed
    or offered to distribute Licensed Products obtained from Synergy in the Territory.
	 	 
	2.6	Performance
    by Affiliates. The Parties agree that their respective rights
    and obligations may be exercised or performed by any of their Affiliates; provided, however, that each Party shall be fully
    responsible and liable for the actions of such Affiliates in the performance of such obligations and shall ensure that such
    Affiliate complies with the terms of this Agreement.
	 	 
	3	REGULATORY
    AND DEVELOPMENT
	 	 
	3.1	Regulatory
    Submissions. Knight shall be solely responsible, at its
    expense, for preparing, filing, and managing any Regulatory Submission and for maintaining any Regulatory Approval for the
    Licensed Products in the Territory. Synergy shall provide reasonable assistance to Knight in making submissions to Governmental
    Authorities and maintaining such Regulatory Approvals. Unless otherwise required by Applicable Law, any Regulatory Approvals
    shall be filed, owned and held in the name of Knight. Knight shall notify Synergy of all Regulatory Submissions that it submits.
	 	 
	3.2	Regulatory
    Correspondence. Each Party shall promptly (and in any event,
    within five (5) Business Days of the date of receipt of notice) notify the other Party in writing of, and shall provide the
    other Party with copies of, any material correspondence received from a Governmental Authority in the Territory. In the event
    that a Party receives any material regulatory letter requiring a response, the other Party will cooperate fully with the receiving
    Party in preparing such response and will promptly provide the receiving Party with any data or information required by the
    Receiving Party in preparing any such response.

 

    	 

    	 

    

  

	3.3	Other
    Covenants of Knight. In addition to its other obligations,
    commitments and undertakings set out in this Agreement, Knight agrees to:

 

	 	(a)	assume
    the reasonable costs of intellectual property fdings, procurement and maintenance for all intellectual property applications
    and registrations associated with the Licensed Products in the Territory, provided that all intellectual property rights relating
    to the Licensed Products shall remain the exclusive property of Synergy ;
	 	 	 
	 	(b)	assume
    all marketing, sales and distribution expenses related to the commercialization of the Licensed Products in the Territory;
    and
	 	 	 
	 	(c)	prepare
    an annual marketing and sales plan relating to the Licensed Products in the Territory.

 

	3.4	Other
    Covenants of Synergy. In addition to its other obligations,
    commitments and undertakings set out in this Agreement, Synergy agrees to:

 

	 	(a)	provide
    Knight with all documentation relating to the submissions for Regulatory Approval to the U S. Food and Drug Administration
    or the European Medicines Agency for the Licensed Products within one (1) month from submission;
	 	 	 
	 	(b)	where
    applicable, provide reasonable assistance to Knight with the Regulatory Submission of the Licensed Products in the Territory;
	 	 	 
	 	(c)	provide
    full assistance and cooperation with respect to securing intellectual property protection in the Territory for the Licensed
    Products;
	 	 	 
	 	(d)	not
    assign the intellectual property associated with Licensed Products to any Third Party;
	 	 	 
	 	(e)	coordinate
    Launch activities with Knight, including pharmacovigilence, pricing, reimbursement, positioning and health care conferences;
	 	 	 
	 	(f)	promptly
    provide United States international marketing and sales materials used for the Licensed Products.

 

	4	TRADEMARKS
	 	 
	4.1	Trade-Mark
    License. Synergy hereby grants to Knight, for the Term,
    an exclusive, royalty-free license to use the Synergy Marks in the Territory in association with the Licensed Products.
	 	 
	4.2	Ownership.
    Knight acknowledges that the Synergy Marks are owned by
    Synergy. The Synergy Marks shall be and remain the sole and exclusive property of Synergy. Knight shall not contest the ownership
    of the Synergy Marks or the validity of any registration relating thereto. Knight agrees, at the request of Synergy, to execute
    any and all proper documents appropriate to assist Synergy in obtaining and maintaining Synergy’s rights in and to the
    Synergy Marks.

 

    	 

    	 

    

 

	4.3	Licensed
    Products to Bear Mark. Licensed Products distributed by
    Knight under this Agreement shall bear the Synergy Marks together with a notice that the Synergy Marks are used under license
    from Synergy, subject to the approval of such labeling by appropriate Governmental Authorities. Knight shall submit to Synergy,
    for prior approval, which shall not be unreasonably withheld, a representative sample of any marketing or promotional materials
    prepared by Knight, bearing the Synergy Marks.
	 	 
	4.4	No
    Similar Mark. Knight will not, without Synergy’s prior
    written consent, register or use in connection with any product, any trade-mark that is confusingly similar to the Synergy
    Marks.
	 	 
	5	COMMERCIALIZATION
	 	 
	5.1	Safety
    Data Exchange Agreement. The parties agree to develop and
    commit to a Safety Data Exchange Agreement (“SDEA”)
    that allows them to fulfill their respective regulatory and pharmacovigilence obligations relating to Adverse Drug
    Event and Adverse Drug Reaction reporting. Such SDEA will be completed within ninety (90) days after the Effective Date.
	 	 
	5.2	Quality
    Complaint Reporting. Knight shall be solely responsible
    for collecting and responding to any product quality complaint relating to the Licensed Products received from a customer
    in the Territory. Synergy shall investigate and provide Knight, in a timely manner, with reports resulting from such investigations.
    If Synergy receives a product quality complaint relating to the Licensed Products from a customer in the Territory, it shall
    investigate and promptly report the investigation results to Knight, who will be solely responsible for communication and
    response, if any, to the customer in the Territory. Furthermore, Synergy shall be responsible for investigating and submitting
    reports to Knight respecting any product quality complaints related to the manufacturing of the Licensed Products.
	 	 
	5.3	Other
    Information. In addition to the foregoing information to
    be provided, each Party shall provide to the other Party with any: (i) information relating to the efficacy and/or safety
    of the Licensed Products, including any recall of the Licensed Products; (ii) complaints from customers, healthcare professionals
    or competitors in the Territory relating to the Licensed Products; (iii) information relating to any potential liability to
    any Third Party in the Territory that is reasonably likely to arise for either Party in connection with the manufacture, or
    Commercialization of the Licensed Products in the Territory; (iv) information relating to any inspections, inquiries, issues
    raised or actions taken by any Governmental Authority in the Territory; and (v) any other information necessary or reasonably
    desirable to enable each Party to comply with any Applicable Law in the Territory or elsewhere.

 

    	 

    	 

    

  

	5.4	Recall.
    Knight shall advise Synergy of any Governmental Authority
    initiated mandatory recall of Licensed Products in the Territory. Knight shall not initiate any voluntary recall of Licensed
    Products in the Territory without prior notice to and consultation with Synergy. Prior to executing any recall of Licensed
    Products in the Territory, Knight shall review with Synergy the proposed manner in which the recall is to be carried out.
    Knight will give due consideration to any reasonable recommendation from Synergy as to the manner of conducting the recall,
    provided that it is agreeable to the applicable Governmental Authority. Knight shall communicate directly with the applicable
    Governmental Authorities in relation to a Licensed Products recall in the Territory. If any Licensed Products recall in the
    Territory results from improper handling, shipping or storage of Licensed Products by Knight, and in no way results from the
    manufacture, control, handling, shipping or storage of the Licensed Products before receipt by Knight, the costs associated
    with the recall shall be paid by Knight and Knight shall indemnify Synergy against any Third Party claims in connection with
    the recall. If the recall results from any cause or issue other than ones for which Knight is responsible as set forth in
    the prior sentence, all costs and expenses arising from the recall, including any costs associated with replacing recalled
    Licensed Products, shall be paid for by Synergy and Synergy shall indemnify Knight against any Third Party Claims in connection
    therewith.
	 	 
	6	MANUFACTURE
    AND SUPPLY
	 	 
	6.1	Manufacture
    by Synergy. During the Term, Knight agrees to obtain exclusively
    from Synergy all Knight’s requirements of the Licensed Products for the Territory. Synergy agrees to supply Knight with
    all of its requirements of Licensed Products as set forth in each order submitted by Knight. Synergy may, at its discretion,
    use the services of a contract manufacturer to manufacture and package the Licensed Products.
	 	 
	6.2	Price.
    Synergy shall supply Licensed Products at a cost to Knight
    equal to Synergy’s Cost of Goods plus ten percent (10%), plus applicable sales taxes. Payment of such amounts shall
    be made by Knight to Synergy within thirty-five (35) days following Knight’s receive of an invoice from Synergy.
	 	 
	6.3	Orders.
    Knight shall order Licensed Products from Synergy by submitting
    purchase orders to Synergy. Such purchase order shall specify, at a minimum, the desired delivery date, unit quantity, place
    of delivery and an order number. Knight shall order Licensed Products. The initial purchase order will have a lead time of
    between sixty (60) and ninety (90) days between the time when an order for Licensed Products is submitted to Synergy until
    the Licensed Products is delivered to Knight. Thereafter, the purchase order will have not less than five (5) Business Days
    lead time
	 	 
	6.4	Delivery
    Terms. Licensed Products will, at Knight’s direction,
    be shipped directly to Knight or to a Third Party in the Territory designated by Knight. The terms for delivery of orders
    of Licensed Products shall be FOB (Incoterms 2010) Synergy’s manufacturer’s facility in the United States.
	 	 
	6.5	Packaging
    and Labeling. Knight shall determine the artwork and design
    for the packaging and labelling in the Territory in consultation with Synergy. Knight shall be entitled to have its trade-marks
    displayed on the packaging for the Licensed Products. Knight shall be responsible for the costs associated with the development
    of Knight’s artwork for the packaging and labeling of the Licensed Products for Launch and for any changes thereto made
    at Knight’s request or for any special packaging required by Knight or a Governmental Authority.

 

    	 

    	 

    

  

	6.6	Specifications.
    Licensed Products manufactured and supplied to Knight hereunder
    shall conform to the Specifications which may be changed from time to time upon mutual agreement, or as required by any Governmental
    Authority.
	 	 
	6.7	GIMP.
    All manufacture and quality control operations by Synergy or its designee shall be in compliance with GMP.
	 	 
	6.8	Shelf
    Life. All Licensed Products supplied by Synergy hereunder
    shall have not less than eighty-five percent (85%) of its shelf life remaining upon delivery to Knight.
	 	 
	6.9	Quality
    Agreement. The Parties shall enter into a quality agreement
    regarding supply of Licensed Products by Synergy to Knight, incorporating provisions that are standard in the pharmaceutical
    field within ninety (90) days of the Effective Date.
	 	 
	6.10	Changes.
    A Party shall promptly notify the other Party in writing
    of all proposed changes, whether voluntary or involuntary, including those arising from a request from a Governmental Authority,
    concerning the quality of Licensed Products and/or documentation or other items for such changes relating to the quality of
    the Licensed Products. The Parties shall negotiate in good faith towards an appropriate response to a Governmental Authority
    in respect of each proposed change in the quality of the Licensed Products including any costs associated with implementing
    said changes. Synergy shall notify Knight of any proposed change in manufacturing facility or manufacturing procedures.
	 	 
	6.11	Minor
    Changes. Minor changes in the procedures for manufacture
    or quality control that do not require approval from a Governmental Authority or that will not affect Regulatory Approvals
    will be communicated by Synergy to Knight in an annual review.
	 	 
	6.12	Release
    to Knight. Synergy, or its designee, shall only release
    for shipment to Knight, finished batches of Licensed Products that have been examined by Synergy for compliance with the Specifications.
    Synergy is responsible for conducting, or having conducted, all required stability and release testing to ensure that the
    finished batches of Licensed Products are in compliance with the Specifications.
	 	 
	6.13	Quality
    Audit. During normal working hours and upon reasonable notice,
    Knight shall be entitled to inspect areas within Synergy’s or its contract manufacturer’s establishment where
    Licensed Products are manufactured or stored, and to inspect the manufacturing, packaging, and quality control records relating
    to the Licensed Products.
	 	 
	6.14	Government
    Inspections. Synergy shall make its internal practices,
    and its manufacturing, packaging, and quality control records relating to the Licensed Products available to Governmental
    Authorities and will allow access to all facilities used for manufacturing the Licensed Products to the applicable Governmental
    Authorities for the purposes of determining Synergy’s compliance with Applicable Laws. Synergy agrees to advise Knight
    immediately of any proposed or announced visit or inspection, and as soon as possible but in any case within three (3) Business
    Days after any unannounced visit or inspection, by a Governmental Authority in the Territory relating to the Licensed Products.
    Synergy shall provide Knight with a reasonable description in writing of each such visit or inspection promptly thereafter,
    and with copies of any letters, reports or other documents issued by any such Governmental Authorities that relate to the
    Licensed Products.

 

    	 

    	 

    

  

	6.15	Defects.
    Any claim by Knight regarding an apparent failure of the
    Licensed Products to comply with the Specifications must be made in writing with full particulars within thirty (30) days
    after receipt of the Licensed Products by Knight. In the case of latent defects, such defects shall be reported to Synergy
    within thirty (30) days of Knight having actual notice of the defect. In case of a justifiable claim for defect because of
    a failure of the Licensed Products to conform to the Specifications, Synergy or its designee shall, without charge, promptly
    replace the defective portion with supplies that are in compliance with such Specifications. Synergy shall assume all costs
    associated with transportation of replacement Licensed Products. Knight shall follow any reasonable instructions to return
    to Synergy or dispose of, in either event at Synergy’s expense, any quantities of Licensed Products as aforesaid that
    are not in compliance with the Specifications.
	 	 
	6.16	Independent
    Lab. If Synergy does not agree with Knight that the Licensed
    Products rejected by Knight fails to conform to the Specifications, the matter will be submitted for analysis to an independent
    laboratory agreed between the Parties. The decision of such independent laboratory following its analysis of the Licensed
    Products shall be final. The cost of the analysis, as well as the costs associated with reasonable shipping, handling, and
    storage of any Licensed Products under dispute as to compliance with the Specifications, shall be borne by the Party who was
    in error.
	 	 
	6.17	Short
    Shipment. If Knight determines that there is a shortage
    in the quantity of any shipment of Licensed Products (from quantities specified in the relevant bill of lading or other shipping
    documents), and it is determined that discrepancy existed at the time it was delivered to Knight from Synergy, Knight shall
    notify Synergy in writing as soon as reasonably possible, and Synergy shall make up the shortage within thirty (30) days of
    such notification at no additional cost to Knight.
	 	 
	6.18	Failure.

 

	 	(a)	In
    the event of any Short Term Inability to Supply the Product in the Territory, Synergy shall be liable for payments to Knight
    as follows: (i) reimbursement for Knight’s share of all Licensed Products lost sales attributable to the Short Term
    Inability to Supply and quantified by Knight using commercially reasonable methods and (ii) all reasonable direct expenses
    incurred by Knight in dealing with and attempting to manage and resolve such Short Term Inability to Supply in the Territory,
    including but not limited to bona fide sales and
    marketing expenses and penalties imposed by distributors and wholesalers. Knight shall attempt to quantify the financial impact
    of any Short Term Inability to Supply, in writing, as soon as reasonably possible to Synergy and shall use all reasonable
    efforts to mitigate such impact. Payments due under this Section 6.18 shall be payable within thirty (30) days of receipt
    of said claim. In the event that two (2) Short Term Inability to Supply events occur within twenty four (24) month period,
    then Synergy shall, upon Knight’s request and Synergy’s expense, be required to enter into a contract manufacturing
    agreement with a Third Party for the manufacture in the Territory and supply of the Licensed Products to the Knight.

 

    	 

    	 

    

  

	 	(b)	In
    the event of a Long Term Inability to Supply, Knight shall be entitled to all of the rights and recourses set forth in Section
    6.18(a). In addition, Knight shall be entitled by notice in writing to terminate the supply arrangements contemplated in this
    Agreement, in which event:

 

	 	(i)	Knight
    shall be entitled to purchase the Licensed Products from a Third Party. For greater certainty. Synergy shall grant to a Third
    Party designated by the Knight the non-exclusive license to use all relevant intellectual property for or in respect of the
    manufacture of the Licensed Products for commercialization in the Territory.
	 	 	 
	 	(ii)	Synergy
    shall provide such assistance as is required by Knight acting reasonably, from time to time to assist in sourcing the Licensed
    Products from a third party.
	 	 	 
	 	(iii)	Without
    limiting the generality of the foregoing. Synergy shall enter into a technology transfer agreement with a Third Party manufacturer
    selected by Knight under which Synergy shall transfer to the selected manufacturer all technical information necessary to
    manufacture the Licensed Products and supply the Licensed Products in the Territory.

 

	6.19	Shortfall.
    In the event of an interruption or shortfall in supply of
    Licensed Products, for whatever reason, that exceeds ninety (90) days in duration, such that not all purchase orders for Licensed
    Products hereunder can be met, then Synergy shall immediately notify Knight and shall allocate a prorated share of its available
    sources and supplies among Knight and Synergy’s other partners (distributors, licensees, agents,) and internal needs,
    based on the respective forecasted commercial supply requirements of each of the parties for that allocation period. In any
    case, the Parties will discuss and agree in good faith on acceptable delivery dates and measures to mitigate the effects of
    the interruption or shortfall. Synergy shall use commercially reasonable efforts to eliminate, cure or overcome such shortage
    and to resume performance of its obligations hereunder as soon as reasonably possible.
	 	 
	6.20	Capacity
    and Supply. Synergy will maintain sufficient manufacturing
    time in its production schedule to provide consistent availability of Licensed Products to meet Knight’s firm orders.
    Synergy shall maintain or cause its contract manufacturer to maintain sufficient volumes of Licensed Products as Knight and
    Synergy, each acting reasonably and based on the then current and anticipated sales, from time to time determine.

 

    	 

    	 

    

  

	6.21	Payment
    Method. All payment due to Synergy hereunder will be paid
    in United States Dollars by wire transfer to an account designated by Synergy.
	 	 
	6.22	Record
    Retention. Synergy will maintain complete and accurate books,
    records, and accounts used for the determination of expenses, deductions, credits, or other relevant factors in connection
    with the calculation of Cost of Goods, in sufficient detail to confirm the accuracy of any payments required under this Agreement,
    which books, records, and accounts will be retained until three (3) years after the end of the period to which such books,
    records, and accounts pertain.
	 	 
	6.23	Audit.
    During the Term of this Agreement and for three (3) years
    thereafter, Knight will have the right to have an independent certified public accounting firm of internationally recognized
    standing access during normal business hours, and upon reasonable prior written notice, to such of the records of Synergy
    as may be reasonably necessary to verify the accuracy of Cost of Goods for any Calendar Quarter. The accounting firm will
    disclose to the Parties only whether the Cost of Goods reported by Synergy is correct or incorrect and the specific details
    concerning any discrepancies. The auditing Party will bear all costs of such audit, unless the audit reveals a discrepancy
    in the auditing Party’s favor of more than five percent (5%), in which case the other Party will bear the cost of the
    audit. Each Party will treat all information subject to review under this Section 6 as Confidential Information and will cause
    its accounting firm to enter into a reasonably acceptable confidentiality agreement obligating such firm to maintain all such
    financial information in confidence pursuant to such confidentiality agreement.
	 	 
	6.24	Payment
    of Additional Amounts. If, based on the results of any audit
    under Section 6.23, payments are owed by one Party to the other under this Agreement, then the Party having such obligation
    will make such payment promptly after the accounting firm’s written report is delivered by courier or registered mail
    to both Parties.
	 	 
	7.	INTELLECTUAL
    PROPERTY
	 	 
	7.1	Notification
    of Third Party Infringement. Each Party shall promptly disclose
    to the other in writing within ten (10) Business Days, any actual, alleged, or threatened Third Party infringement or misappropriation
    in the Territory of any Synergy Patent and any actual, alleged or threatened infringement or passing off of the Synergy Mark,
    of which such Party becomes aware.

 

    	 

    	 

    

  

	7.2	Response
    to Third Party Infringement. Synergy shall have the first
    right, but not any obligation, to respond to any actual or threatened infringement of an Synergy Patent, the Synergy Mark
    or of any unfair trade practices, trade dress imitation, passing off of counterfeit goods, or like offenses in the Territory
    relating to the Licensed Products. If Synergy elects to respond to any actual or threatened infringement by initiating a proceeding.
    Synergy shall use legal counsel of its choice at its expense and shall have full control over the conduct of such proceeding.
    Synergy may settle or compromise any such proceeding without the consent of Knight; provided, however, that if such settlement
    affects Knight’s rights under this Agreement, or Knight’s ability to Commercialize the Licensed Products within
    the Territory, or otherwise requires Knight to admit wrongdoing, fault, or liability. Synergy will not settle or compromise
    any such proceeding without the consent of Knight, such consent not to be unreasonably withheld, conditioned, or delayed.
    If Synergy elects not to respond to any actual or threatened infringement of an Synergy Patent, the Synergy Mark or of any
    unfair trade practices, trade dress imitation, passing off of counterfeit goods, or like offenses in the Territory relating
    to the Licensed Products, then Knight shall have the right, but not the obligation, to take action, at its sole expense, in
    which case Knight shall have full control over the conduct of such proceeding and Knight may settle or compromise any such
    proceeding without the consent of Synergy; provided, however, that if such settlement affects Synergy’s intellectual
    property rights or its rights under this Agreement, or Synergy’s ability to Commercialize the Licensed Products outside
    the Territory, or otherwise requires Synergy to admit wrongdoing, fault, or liability, Knight will not settle or compromise
    any such proceeding without the consent of Synergy, such consent not to be unreasonably withheld, conditioned, or delayed.
    Knight shall be solely responsible for any legal costs or damages awards made in any proceeding that is initiated by Knight
    in the event that Synergy elects not to respond to any actual or threatened infringement.
	 	 
	7.3	Cooperation.
    Each Party shall cooperate reasonably, at its expense, in
    any enforcement effort initiated by the other Party. The Parties nor their Affiliates shall contest any joinder in any proceeding
    sought to be brought by the other Party if such joinder is required by Law.
	 	 
	7.4	Recovery.
    Except as otherwise agreed to by the Parties as part of
    a cost-sharing arrangement, any monetary award recovered from a Third Party in connection with any proceeding initiated to
    protect, maintain, defend, or enforce any intellectual property in the Territory or recovered from a Third Party in connection
    with any proceeding initiated for infringement or misappropriation of intellectual property shall first be used to reimburse
    the Parties for any out-of-pocket legal expenses relating to such proceeding and the balance being retained by the Party that
    brought and controlled such litigation.
	 	 
	7.5	Infringement
    of Third Party IP. If either Party becomes aware that its
    activities performed hereunder may constitute actual or alleged infringement or misappropriation of the intellectual property
    rights of a Third Party, it shall promptly notify the other Party and the Parties shall discuss a strategy to defend or mitigate
    against any actual or alleged infringement.
	 	 
	8.	REPRESENTATION
    AND WARRANTIES
	 	 
	8 1 	Synergy
    Covenants, Representations and Warranties Synergy covenants,
    represents and warrants (as the case may be) to Knight that:

 

	 	(a)	Synergy
    is a corporation duly organized, validly existing and in good standing under the laws of Nevada;

 

    	 

    	 

    

 

	 	(b)	Synergy
    has the legal right and authority to enter into this Agreement;
	 	 	 
	 	(c)	Synergy
    has taken all necessary actions to authorize the execution, delivery and performance of this Agreement;
	 	 	 
	 	(d)	Synergy
    has obtained all consents, licenses and authorizations that are necessary to perform its obligations under this Agreement;
	 	 	 
	 	(e)	Upon
    the execution and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of Synergy, enforceable
    against Synergy in accordance with its terms, except to the extent enforceability is limited by bankruptcy, insolvency or
    similar laws affecting creditors’ rights and remedies or equitable principles;
	 	 	 
	 	(f)	The
    performance of Synergy’s obligations under this Agreement will not conflict with its organizational documents, as amended,
    or result in a breach of any material agreements or contracts to which it is a party;
	 	 	 
	 	(g)	Synergy
    has not and will not, during the term of this Agreement, enter into any material agreements or contracts that would conflict
    with its obligations under this Agreement;
	 	 	 
	 	(h)	Synergy
    owns or licenses all of the Synergy Patents licensed to Knight pursuant to this Agreement and the Synergy Patents licensed
    to Knight pursuant to this Agreement are all of the patents owned or licensed by Synergy that are reasonably necessary for
    Knight to carry out its obligations and exercise its rights under this Agreement;
	 	 	 
	 	(i)	Synergy
    has not received any notice that the manufacture, sale, or use of the Licensed Products in the Territory infringes upon any
    intellectual property rights of any Third Parties in the Territory;
	 	 	 
	 	(j)	Synergy
    has not received any notice from a Third Party that any issued Synergy Patent is invalid or unenforceable for any reason;
	 	 	 
	 	(k)	To
    the knowledge of Synergy, there are no activities being carried out by Third Parties in the Territory that would constitute
    infringement or misappropriation of the Synergy Patents or the Synergy Mark;
	 	 	 
	 	(l)	Licensed
    Products manufactured by Synergy and provided to Knight pursuant to this Agreement will meet the Specifications at the time
    of delivery to Knight and will have been manufactured in accordance with the requirements of GMP.

 

	8.2	Knight
                                         Representations and Warranties. Knight
                                         covenants, represents and warrants to
	 	 
	 	Synergy
                                         (as the case may be) as follows:

  

	 	(a)
    	Knight
    is a corporation duly organized, validly existing and in good standing, under the laws of Barbados.

 

    	 

    	 

    

  

	 	(b)	Knight
    has the legal right, authority, and power to enter into this Agreement.
	 	 	 
	 	(c)	Knight
    has taken all necessary action to authorize the execution, delivery, and performance of this Agreement.
	 	 	 
	 	(d)	Upon
    the execution and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of Knight, enforceable
    against Knight in accordance with its terms, except to the extent enforceability is limited by bankruptcy, insolvency or similar
    laws affecting creditors’ rights and remedies or equitable principles.
	 	 	 
	 	(e)	The
    performance of Knight’s obligations under this Agreement will not conflict with its organizational documents or result
    in a breach of any material agreements or contracts to which any is a party.
	 	 	 
	 	(f)	Knight
    has not and will not, during the term of this Agreement, enter into any material agreements or contracts that would be inconsistent
    with its obligations under this Agreement.
	 	 	 
	 	(g)	Neither
    Knight nor its Affiliates will initiate a proceeding to challenge the validity or enforceability of any Synergy Patent or
    the Synergy Marks, or directly or indirectly assist any Third Party with respect to any such proceeding.

 

	8.3	WARRANTY
    DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT,
    NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY EXPRESS
    OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE LICENSED PRODUCTS OR ANY
    TECHNOLOGY OR ANY LICENSE GRANTED BY EITHER PARTY HEREUNDER. SYNERGY DOES NOT WARRANT NOR REPRESENT THAT ANY OF THE SYNERGY
    PATENTS ARE VALID OR ENFORCEABLE
	 	 
	8.4	LIMITATIONS
    OF LIABILITY. WITHOUT LIMITING THE PARTIES’ OBLIGATIONS
    REGARDING INDEMNIFICATION, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR TO ANY THIRD PARTY WHO MAY BENEFIT FROM ANY
    PROVISION OF THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES (INCLUDING DAMAGES RESULTING
    FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT
    OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER
	 	 
	8.5	Indemnification
    by Synergy. Synergy hereby agrees to defend, indemnify,
    and hold Knight, its Affiliates and their respective officers, directors, employees and agents, (each a “Knight
    Indemnified Party”) harmless from and against any Third Party’s claims for loss, damage, or liability
    resulting from: (i) any breach of this Agreement or any warranty or covenant provided in this Agreement by Synergy or an Affiliate
    of Synergy; (ii) any violation of Applicable Law by Synergy or its Affiliates; and (iii) any negligent act or omission or
    willful misconduct of Synergy or its Affiliates; (iv) any claim that the sale by Knight or its Affiliates, of the Licensed
    Products infringes on intellectual property rights in the Territory of any other person; (v) any claim arising from any use,
    within the approved labelling, made by any person of any of the Licensed Products; in all cases, except to the extent such
    Third Party’s claim for loss, damage or liability is the result of: (i) any breach of this Agreement by Knight or a
    Knight Indemnified Party, (ii) any violation of Applicable Law by Knight or a Knight Indemnified Party, or (iii) any negligent
    act or omission or willful misconduct of Knight or a Knight Indemnified Party.

 

    	 

    	 

    

  

	8.6	Indemnification
    by Knight. Knight hereby agrees to defend, indemnify, and
    hold Synergy, its Affiliates and their respective officers, directors, employees and agents, (each a “Synergy
    Indemnified Party”) harmless from and against any Third Party’s claims for loss, damage, or liability
    resulting from: (i) any breach of this Agreement or any warranty or covenant provided in this Agreement by Knight or an Affiliate
    of Knight; (ii) any violation of Applicable Law by Knight or its Affiliates; and (iii) any negligent act or omission or willful
    misconduct of Knight or its Affiliates; in all cases, except to the extent such Third Party’s claim for loss, damage
    or liability is the result of: (i) any breach of this Agreement by Synergy or an Synergy Indemnified Party, (ii) any violation
    of Applicable Law by Synergy or an Synergy Indemnified Party, or (iii) any negligent act or omission or willful misconduct
    of Synergy or an Synergy Indemnified Party.
	 	 
	 	 
	8.7	Indemnification
    Procedure. If an indemnified party intends to claim indemnification
    under this Section 8, such party shall promptly notify the other party of any loss, claim, damage, liability or action in
    respect of which the indemnified party intends to claim such indemnification, and the indemnifying party shall have a first
    opportunity to assume the sole defense thereof with counsel selected by the indemnifying party and approved by the indemnified
    party acting reasonably; provided, however, that an indemnified party shall have the right to retain its own counsel and participate
    fully in the defense, with the fees and expenses to be paid by the indemnified party. The failure or delay to deliver notice
    to the indemnifying party, within a reasonable time after the commencement of any such proceeding, if irreparably prejudicial
    to the indemnifying party’s ability to defend such proceeding, shall relieve the indemnifying party of any and all liability
    to the indemnified party under this Section 8. The indemnified party shall cooperate fully with the indemnifying party and
    their legal representatives in the investigation of any loss, claim, damage, or liability covered by this indemnification,
    and shall mitigate such loss and damages. Any amount payable in order to satisfy an indemnity hereunder shall be paid as soon
    as reasonably possible after the indemnified party has incurred an indemnified expense and notified the indemnifying party
    thereof.
	 	 
	8.8	Compliance
    with Law. Each Party shall comply, and shall require their
    Affiliates and permitted sublicensees to comply, with all Applicable Laws relative to their obligations hereunder.
	 	 
	8.9	Insurance.
    The Parties shall maintain insurance, including product
    liability insurance, that is adequate to cover their obligations hereunder and that is consistent with normal business practices
    of prudent corporations engaged in the same or a similar business. The Parties acknowledge and agree that such insurance shall
    not be construed to create a limit with respect to their indemnification obligations.

 

    	 

    	 

    

  

	9.	TERM
    AND TERMINATION
	 	 
	9.1	Term.
    This Agreement will take effect from the Effective Date
    and, unless earlier terminated in accordance with the terms herein, will continue in full force and effect for fifteen (15)
    years from the Launch (the “Initial Term”). This
    Agreement shall automatically renew for successive fifteen (15) year periods (each a “Renewal
    Term”) unless, at least one (1) year prior to the expiry of the Initial Term or Renewal Term, either Party
    provides the other with written notice of its intention not to renew the Agreement (a “Non-Renewal
    Notice”) at the end of the applicable period, and further provided that if the notifying Party is Synergy,
    it shall be obliged to pay to Knight the Non-Renewal Fee set out in Section 9.7 below.
	 	 
	9.2	Termination
    for Breach. Either Party may terminate this Agreement by
    written notice to the other Party with immediate effect in the following cases:

 

	 	(a)	In
    the event of a petition in bankmptcy or insolvency of the other Party, or in case of the filing by the other Party of any
    petition or answer seeking reorganization, readjustment, or rearrangement of its business under any law or any government
    regulation relating to bankruptcy or insolvency, or in case of the institution by the other Party of any proceedings for the
    liquidation or winding up of its business, or for the termination of its corporate charter.
	 	 	 
	 	(b)	If
    the other Party is otherwise in material default or breach of this Agreement and such default or breach is not cured within
    (i) sixty (60) days after written notice thereof is delivered to the defaulting or breaching Party (thirty (30) days in the
    case of Knight’s failure to pay any amounts due hereunder), or (ii) in the case of a breach that cannot be cured within
    sixty (60) days, within a reasonable period not exceeding one hundred twenty (120) days after written notice thereof is delivered
    to the defaulting or breaching Party.

 

	9.3	Termination
    of Knight. Knight may terminate this Agreement in whole
    or in part (with respect to a particular Licensed Product Territory or Additional Territory) by notice in writing given no
    less than sixty (60) days prior to the intended termination date.
	 	 
	9.4	Effect
    of Termination. Upon expiry or termination of this Agreement,
    all licenses and rights granted by Synergy hereunder shall terminate and Knight undertakes to:

 

	 	(a)	except
    as provided for in Section 9.6, cease any Commercialization of the Licensed Products in the Territory; and
	 	 	 
	 	(b)	within
    thirty (30) days or expiry or termination, transfer title to all current and pending Regulatory Approvals for the Licensed
    Products to Synergy and assist Synergy, at Synergy’s cost, in submitting appropriate documents to transfer the Regulatory
    Approvals for the Licensed Products to Synergy or its designee.

 

    	 

    	 

    

  

	9.5	Survival.
    In the event of the termination of this Agreement for any
    reason, the following provisions of this Agreement shall survive Sections 1, 7, 9, 10 and 12 and any other terms which, by
    their nature, require or contemplate performance by the Parties after expiry or termination. In any event, termination of
    this Agreement shall not relieve the Parties of any liability which accrued hereunder prior to the effective date of such
    termination.
	 	 
	9.6	Sell-Off
    of Inventory. Upon termination of this Agreement, Knight
    shall be entitled to sell off any inventory of the Licensed Products in Knight’s possession or control or which are
    subject to binding purchase orders on the date such termination is effective.
	 	 
	9.7	Non-Renewal
    Fee. In the event that Synergy issues a Non-Renewal Notice,
    it shall be obliged to pay to Knight an amount equal to the Net Sales of the Licensed Products as achieved by Knight in the
    Territory during the eight (8) Calendar Quarters preceding the date of such notice, plus all applicable taxes (the “Non-Renewal
    Fee”). Within sixty (60) days of its receipt of the Non-Renewal Notice, Knight shall issue an invoice for
    the payment of the Non-Renewal Fee which shall include reasonable details as to the calculation of the said amount. The Non-Renewal
    Fee shall be payable by Synergy within thirty (30) days of the issuance of the said invoice.
	 	 
	10.	DISPUTE
    RESOLUTION
	 	 
	10.1	Arbitration.
    Except as otherwise expressly provided herein, any dispute
    or claim arising out of or relating to this Agreement, or to the breach, termination, or validity of this Agreement, will
    be resolved as follows: each Party shall discuss the matter and make reasonable efforts to attempt to resolve the dispute.
    If the Parties are unable to resolve, the dispute a CEO or President of each Party will meet within thirty days (30) of a
    request to attempt to resolve such dispute being made by a Party. If the CEOs or Presidents cannot resolve the dispute through
    good faith negotiations within sixty (60) days after a Party requests such meeting, then the Parties shall resort to binding
    arbitration before a single arbitrator using the arbitration procedures set forth under the simplified rules of the American
    Arbitration Association under its Commercial Arbitration Rules. Any hearing in the course of the arbitration shall be held
    in New York New York in the English language. The decision of the arbitrator shall be final and not subject to appeal and
    the arbitrator may apportion the costs of the arbitration, including the reasonable fees and disbursements of the parties,
    between or among the parties in such manner as the arbitrator considers reasonable. All matters in relation to the arbitration
    shall be kept confidential to the full extent permitted by law, and no individual shall be appointed as an arbitrator unless
    he or she agrees in writing to be bound by this provision.
	 	 
	10.2	Irreparable
    Harm. Notwithstanding anything to the contrary in Section
    10.2, if either Party in its sole judgment, acting reasonably, believes that any such dispute could cause it irreparable harm,
    such Party (i) will be entitled to seek equitable relief in order to avoid such irreparable harm and (ii) will not be required
    to follow the procedures set forth in Section 10.2.

 

    	 

    	 

    

  

	11.	KNIGHT
    OPTION FOR ADDITIONAL TERRITORIES
	 	 
	 	Knight
    (directly or through one of its Affdiates) shall have the option to become Synergy’s exclusive distribution partner
    for either or both of the Licensed Products in any one or more of Israel, Russia and Sub-Saharan Africa (each an “Additional
    Territory”) under the same terms and conditions as this Agreement. Knight shall inform Synergy of its intention
    to exercise such right (directly or through one of its Affdiates) at any time or from time to time by notice in writing. If
    Knight exercises such right, then the said Additional Territories and the Licensed Product(s) referred to in such Territory
    shall be deemed to be part of the “Territory” for all purposes of this Agreement. Where the option is exercised
    on behalf of a Knight Affiliate, the parties shall enter into a separate and identified agreement concerning the particular
    Licensed Product and Additional Territory.

  

	12.	OTHER
    PROVISIONS
	 	 
	12.1	Withholding
    Tax. Knight will make all payments to Synergy under this
    Agreement without deduction or withholding for taxes except to the extent that any such deduction or withholding is required
    by law in effect at the time of payment. Any tax required to be withheld on amounts payable by Knight under this Agreement
    will be timely paid by Knight on behalf of Synergy to the appropriate Governmental Authority, and Knight will furnish Synergy
    with the corresponding proof of payment of such tax, as may be required in order to enable Synergy to request reimbursement
    or deduction of the withheld amount, or to otherwise comply with its duties. Knight and Synergy agree to cooperate to legally
    minimize and reduce such withholding taxes and provide any information or documentation required by any taxing authority.
	 	 
	12.2	Further
    Assurances. Upon request by either Party and at such Party’s
    expense, the other Party shall do such further acts and execute such additional agreements and instruments as may be reasonably
    necessary to give effect to the purposes of this Agreement.
	 	 
	12.3	Independent
    status. Each Party shall act as an independent contractor
    and shall not bind nor attempt to bind the other Party to any contract, nor any performance of obligations outside of the
    license agreement. Nothing contained or done under the Agreement shall be interpreted as constituting either Party the agent
    of the other in any sense of the term whatsoever or in the relationship of partners or joint venturers.
	 	 
	12.4	Assignment.
    Except in connection with the acquisition of a Party or
    the sale of all or substantially all of the assets of such Party, this Agreement may not be, directly or indirectly, assigned
    or transferred, in whole or in part, by a Party to a Third Party without the prior written consent of the other Party. The
    rights and obligations contained herein shall enure to the benefit of each Party’s successors and permitted assigns,
    and shall be binding on and enforceable against the relevant Party’s successors and permitted assigns. Any reference
    in this Agreement to any Party shall be construed accordingly.

 

    	 

    	 

    

  

	12.5	Compliance
    with law. Each Party shall comply with, and shall not be
    in violation of any valid applicable international, national, provincial or local statutes, laws, ordinances, rules, regulations,
    or other governmental orders of the Territory.
	 	 
	12.6	Force
    Majeure. No Party shall be responsible for a failure or
    delay in performance of any of the obligations hereunder due wars, insurrections, strikes, acts of God, power outages, storms,
    or actions of regulatory agencies (such events being defined as “Force
    Majeure”), provided that the Party seeking relief from its obligations advises the other Party forthwith
    of the Force Majeure. A Party whose performance of obligations has been delayed by force majeure shall use commercially reasonable
    efforts to overcome the effect of the Force Majeure as soon as possible. The other Party will have no right to demand indemnity
    for damage or assert a breach against such Party, provided, however, that if the event of Force Majeure preventing performance
    shall continue for more than six (6) months and such underlying cause would not also prevent other parties from performing
    such obligations, then the Party not subject to the event of Force Majeure may terminate this Agreement with a written notice
    to the other without any liability hereunder, except the obligation to make payments due to such date.
	 	 
	12.7	Notices
    and Amendments. Any notice or other communication required
    or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication
    or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall
    be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the
    time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section
    12.7. Notices and other communications shall be addressed as follows:

 

	 	(a)
    In the case of Synergy:
	 	 	 
	 		Synergy
    Strips Corp.

    c/o Jack Ross 865 Spring 

    Street Westbrook, Maine 04092 

    Fax:
	 	 	 
	 	E-mail:	jack.ross@purebrands.ca
	 	 	 
	 	with
    a copy to:
	 	Wyrick
    Robbins Yates & Ponton LLP 
 4101 Lake Boone Trail, Suite
    300 
 Raleigh, North Carolina 27607 U.S.A.
	 	Attention:	W.
    David Mannheim, Esq.
	 	Fax:	(919)
    781-4865
	 	E-mail:	dmann
    heim@ wy ri ck. c om

 

    	 

    	 

    

  

	 	Knight
    Therapeutics (Barbados) Inc.
	 	Chancery
    House High Street
	 	Bridgetown,
    St. Michael
	 	BB11128	 
	 	Barbados,
    WI
	 	Attention:	Andrew
    C. Ferreira
	 	Fax:	1-246-431-0076
	 	 	 
	 	With
    a copy to:
	 	 	 
	 	Davies
    Ward Phillips & Vineberg LLP 900 Third Avenue 24th Floor
	 	New
    York, NY 10022
	 	LJ.S.A.	 
	 	Attention:	Hillel
    W. Rosen
	 	Fax:	(212)308-0132

 

	12.8	Complete
    Agreement. This Agreement together with the SDEA, and the
    Quality Agreement, embodies all of the understandings and obligations between the Parties with respect to the Licensed Products
    and supersedes any prior or contemporaneous agreements and understandings, whether written or oral, between the Parties with
    respect to the subject matter hereof. Any amendments or supplements to this Agreement shall not be valid unless executed in
    writing by duly authorized officers of both parties.
	 	 
	12.9	Waiver.
    No failure to exercise and no delay in exercising any right
    or remedy hereunder shall operate as a waiver thereof. Any waiver granted hereunder shall only be applicable the specific
    acts covered thereby and shall not apply to any subsequent events, acts, or circumstances.
	 	 
	12.10	Severability.
    In the event any portion of this Agreement shall be held
    illegal, void or ineffective, the remaining portion hereof shall remain in full force and effect. If any of the terms or provisions
    of this Agreement are in conflict with any applicable statute or rule of law, then such terms or provisions shall be deemed
    inoperative to the extent that they may conflict therewith and shall be deemed to be modified to conform with such statute
    or rule of law.
	 	 
	12.11	Governing
    Law. This Agreement all disputes arising out of or relating
    to this Agreement, or the performance, enforcement, breach or termination hereof or thereof, and any remedies relating thereto,
    shall be construed, governed by and interpreted in accordance with the laws of the State of New York.

 

    	 

    	 

    

  

	12.12	Public
    Announcements. Neither Party shall originate any publicity,
    news release, or public announcements relating to this Agreement (including, without limitation, its existence, its subject
    matter, the Parties’ performance, any amendment hereto, or performance hereunder), whether to the public or press, stockholders,
    or otherwise, without the prior written consent of the other Party, save only such announcements that are required by law
    or the rules of any relevant stock exchange to be made or that are otherwise agreed to by the Parties. If a Party decides
    to make an announcement, whether required by law or otherwise, it shall give the other Party reasonable notice of the text
    of the announcement so that the other Party shall have an opportunity to comment upon the announcement. To the extent that
    the receiving Party reasonably requests the deletion of any information in any such announcement, the disclosing Party shall
    delete such information unless, in the opinion of the disclosing Party’s legal counsel, such information is required
    by law or the rules of any relevant stock exchange to be disclosed. The timing and content of the initial press release relating
    to this Agreement, if any, including its existence, the subject matter to which it relates and the transactions contemplated
    herein will, except as otherwise required by law or any stock exchange rules, be determined jointly by the Parties.
	 	 
	12.13	Counterparts.
    This Agreement may be executed in any number of counterparts,
    each of which shall be considered one and the same Agreement and shall become effective when a counterpart hereof has been
    signed by each of the Parties and delivered to the other Party.
	 	 
	12.14	Time
    of Essence. Time shall be of the essence of this Agreement
    and of each provision hereof.
	 	 
	12.15	English
    Language. At the request of the parties, this Agreement
    and the other Loan Documents have been negotiated in the English language and will be or have been executed in the English
    language. Les soussignes out expressement demande que ce document
    et tons les documents annexes soient rediges en langue anglaise.

 

(Signature
page follows)

 

    	 

    	 

    

 

IN WITNESS
WHEREOF, the parties have signed this Agreement.

 

	By:	/s/
    Jack Ross	 	By:	/s/
    [Unintelligible]
	Name:	JACK ROSS	 	Name:	CHANCERY
    CORPORATE SERVICES LIMITED
	Title:	CEO	 	Title:	SECRETARY

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]